CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CEL-SCI (NYSE:CVM) in a research note published on Saturday morning. The firm issued a sell rating on the stock.

CEL-SCI Trading Down 3.5 %

Shares of CVM opened at $0.23 on Friday. CEL-SCI has a 1-year low of $0.22 and a 1-year high of $2.39. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $0.35 and its 200-day moving average price is $0.61. The firm has a market capitalization of $18.46 million, a price-to-earnings ratio of -0.48 and a beta of 0.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Thoroughbred Financial Services LLC grew its stake in CEL-SCI by 40.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after purchasing an additional 54,900 shares during the period. Plotkin Financial Advisors LLC bought a new stake in shares of CEL-SCI during the 3rd quarter valued at $98,000. Finally, Geode Capital Management LLC boosted its holdings in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.